Symbols / PRQR Stock $1.55 -4.91% ProQR Therapeutics N.V.
PRQR (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Ratings
Current target
$1.55
Low
$4.00
High
$14.00
Mean
$8.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-09 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-11-04 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-06-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2025-06-27 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2025-05-13 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-04-29 | init | Evercore ISI Group | — → Outperform | $5 |
| 2025-03-14 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-03-14 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-12 | init | Jones Trading | — → Buy | $11 |
| 2024-12-12 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-12-12 | main | Chardan Capital | Buy → Buy | $4 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-29 | up | Raymond James | Outperform → Strong Buy | $14 |
| 2024-05-10 | main | Chardan Capital | Buy → Buy | $3 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-18 | main | Citigroup | Neutral → Neutral | $2 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-14 | main | Chardan Capital | Buy → Buy | $3 |
- ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell? - MarketBeat Sat, 25 Apr 2026 08
- ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat Sun, 26 Apr 2026 06
- ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha Fri, 10 Apr 2026 07
- Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance Wed, 25 Mar 2026 07
- ProQR picks rare liver disease for lead drug as more data nears - Stock Titan Wed, 08 Apr 2026 07
- Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st ue, 13 Jan 2026 08
- ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery - The Globe and Mail hu, 09 Apr 2026 07
- ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - GlobeNewswire Wed, 08 Apr 2026 07
- PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus hu, 09 Apr 2026 17
- ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 12 Mar 2026 07
- ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha Wed, 08 Apr 2026 07
- Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance Sun, 29 Mar 2026 07
- Co-founder among 2 ProQR directors set to leave board at 2026 AGM - Stock Titan Mon, 09 Feb 2026 08
- ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - Seeking Alpha Wed, 08 Apr 2026 07
- ProQR Therapeutics: Not A Needle Mover Just Yet - Seeking Alpha Sat, 06 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
15.91
-15.86%
|
18.91
+190.22%
|
6.51
+81.25%
|
3.59
|
| Operating Revenue |
|
15.91
-15.86%
|
18.91
+190.22%
|
6.51
+81.25%
|
3.59
|
| Operating Expense |
|
59.35
+20.20%
|
49.38
+19.55%
|
41.30
-39.92%
|
68.75
|
| Research And Development |
|
44.73
+23.04%
|
36.36
+44.57%
|
25.15
-50.56%
|
50.87
|
| Selling General And Administration |
|
15.06
+10.24%
|
13.66
-15.86%
|
16.24
-12.95%
|
18.65
|
| General And Administrative Expense |
|
15.06
+10.24%
|
13.66
-15.86%
|
16.24
-12.95%
|
18.65
|
| Other Gand A |
|
15.06
+10.24%
|
13.66
-15.86%
|
16.24
-12.95%
|
18.65
|
| Other Operating Expenses |
|
-0.44
+31.09%
|
-0.64
-700.00%
|
-0.08
+89.54%
|
-0.77
|
| Total Expenses |
|
59.35
+20.20%
|
49.38
+19.55%
|
41.30
-39.92%
|
68.75
|
| Operating Income |
|
-43.45
-42.58%
|
-30.47
+12.41%
|
-34.79
+46.61%
|
-65.16
|
| Total Operating Income As Reported |
|
-43.45
-42.58%
|
-30.47
+4.35%
|
-31.86
+51.11%
|
-65.16
|
| EBITDA |
|
-38.53
-59.74%
|
-24.12
-0.10%
|
-24.10
+57.32%
|
-56.46
|
| Normalized EBITDA |
|
-38.17
-58.30%
|
-24.11
+16.07%
|
-28.73
+51.98%
|
-59.83
|
| Reconciled Depreciation |
|
2.70
-2.10%
|
2.76
+9.87%
|
2.51
-0.32%
|
2.52
|
| EBIT |
|
-41.24
-53.39%
|
-26.88
-1.03%
|
-26.61
+54.88%
|
-58.98
|
| Total Unusual Items |
|
-0.36
-5014.29%
|
-0.01
-100.15%
|
4.63
+37.63%
|
3.37
|
| Total Unusual Items Excluding Goodwill |
|
-0.36
-5014.29%
|
-0.01
-100.15%
|
4.63
+37.63%
|
3.37
|
| Special Income Charges |
|
0.00
|
0.00
-100.00%
|
4.89
+451.73%
|
-1.39
|
| Other Special Charges |
|
—
|
—
|
-1.87
-234.24%
|
1.39
|
| Net Income |
|
-42.18
-51.94%
|
-27.76
+1.27%
|
-28.12
+56.35%
|
-64.42
|
| Pretax Income |
|
-42.16
-50.80%
|
-27.96
-0.53%
|
-27.81
+56.62%
|
-64.11
|
| Net Non Operating Interest Income Expense |
|
1.40
-35.42%
|
2.17
+56.40%
|
1.39
+127.68%
|
-5.02
|
| Interest Expense Non Operating |
|
0.93
-13.74%
|
1.08
-10.47%
|
1.20
-76.54%
|
5.13
|
| Net Interest Income |
|
1.40
-35.42%
|
2.17
+56.40%
|
1.39
+127.68%
|
-5.02
|
| Interest Expense |
|
0.93
-13.74%
|
1.08
-10.47%
|
1.20
-76.54%
|
5.13
|
| Interest Income Non Operating |
|
2.33
-28.24%
|
3.25
+25.38%
|
2.59
+2346.23%
|
0.11
|
| Interest Income |
|
2.33
-28.24%
|
3.25
+25.38%
|
2.59
+2346.23%
|
0.11
|
| Other Income Expense |
|
-0.12
-136.39%
|
0.34
-93.95%
|
5.59
-7.99%
|
6.07
|
| Other Non Operating Income Expenses |
|
0.23
-31.88%
|
0.34
-63.80%
|
0.95
-64.87%
|
2.71
|
| Gain On Sale Of Security |
|
-0.36
-5014.29%
|
-0.01
+97.25%
|
-0.26
-105.36%
|
4.76
|
| Gain On Sale Of Business |
|
0.00
|
0.00
-100.00%
|
0.09
|
0.00
|
| Tax Provision |
|
0.02
+109.64%
|
-0.20
-152.56%
|
-0.08
-181.25%
|
0.10
|
| Tax Rate For Calcs |
|
0.00
+2900.00%
|
0.00
+133.33%
|
0.00
-98.57%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.08
-153328.57%
|
-0.00
-100.35%
|
0.01
-98.03%
|
0.71
|
| Net Income Including Noncontrolling Interests |
|
-42.18
-51.94%
|
-27.76
-0.10%
|
-27.73
+56.80%
|
-64.20
|
| Net Income From Continuing Operation Net Minority Interest |
|
-42.18
-51.94%
|
-27.76
+1.27%
|
-28.12
+56.35%
|
-64.42
|
| Net Income From Continuing And Discontinued Operation |
|
-42.18
-51.94%
|
-27.76
+1.27%
|
-28.12
+56.35%
|
-64.42
|
| Net Income Continuous Operations |
|
-42.18
-51.94%
|
-27.76
-0.10%
|
-27.73
+56.80%
|
-64.20
|
| Minority Interests |
|
0.00
|
0.00
+100.00%
|
-0.38
-74.55%
|
-0.22
|
| Normalized Income |
|
-41.90
-50.96%
|
-27.76
+15.22%
|
-32.74
+51.20%
|
-67.08
|
| Net Income Common Stockholders |
|
-42.18
-51.94%
|
-27.76
+1.27%
|
-28.12
+56.35%
|
-64.42
|
| Diluted EPS |
|
—
|
-0.32
+8.57%
|
-0.35
+61.11%
|
-0.90
|
| Basic EPS |
|
—
|
-0.32
+8.57%
|
-0.35
+61.11%
|
-0.90
|
| Basic Average Shares |
|
—
|
86.09
+6.26%
|
81.01
+13.08%
|
71.64
|
| Diluted Average Shares |
|
—
|
86.09
+6.26%
|
81.01
+13.08%
|
71.64
|
| Diluted NI Availto Com Stockholders |
|
-42.18
-51.94%
|
-27.76
+1.27%
|
-28.12
+56.35%
|
-64.42
|
| Earnings From Equity Interest |
|
—
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Gain On Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
2.93
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
112.76
-32.87%
|
167.96
+21.81%
|
137.88
-19.52%
|
171.32
|
| Current Assets |
|
100.13
-34.92%
|
153.84
+27.16%
|
120.99
-21.67%
|
154.46
|
| Cash Cash Equivalents And Short Term Investments |
|
92.41
-38.15%
|
149.41
+25.63%
|
118.92
+25.48%
|
94.78
|
| Cash And Cash Equivalents |
|
92.41
-38.15%
|
149.41
+25.63%
|
118.92
+25.48%
|
94.78
|
| Cash Equivalents |
|
54.66
-27.33%
|
75.21
+27.15%
|
59.15
|
0.00
|
| Cash Financial |
|
37.76
-49.12%
|
74.20
+24.13%
|
59.77
-36.93%
|
94.78
|
| Receivables |
|
5.09
+150.91%
|
2.03
+59.86%
|
1.27
-97.78%
|
57.24
|
| Accounts Receivable |
|
3.36
|
0.00
|
—
|
—
|
| Other Receivables |
|
0.81
-39.04%
|
1.34
+79.46%
|
0.74
-98.68%
|
56.63
|
| Taxes Receivable |
|
0.91
+32.32%
|
0.69
+31.93%
|
0.52
-13.84%
|
0.61
|
| Prepaid Assets |
|
2.63
+9.00%
|
2.41
+203.91%
|
0.79
-67.62%
|
2.45
|
| Total Non Current Assets |
|
12.63
-10.51%
|
14.11
-16.48%
|
16.90
+0.21%
|
16.86
|
| Net PPE |
|
12.63
-10.51%
|
14.11
-16.48%
|
16.90
+4.05%
|
16.24
|
| Gross PPE |
|
33.29
+3.80%
|
32.07
-0.07%
|
32.09
+10.23%
|
29.11
|
| Accumulated Depreciation |
|
-20.66
-15.05%
|
-17.96
-18.17%
|
-15.20
-18.03%
|
-12.87
|
| Properties |
|
24.19
+1.67%
|
23.79
-3.96%
|
24.77
+8.36%
|
22.86
|
| Other Properties |
|
9.10
+9.93%
|
8.28
+13.11%
|
7.32
+17.05%
|
6.25
|
| Investments And Advances |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.62
|
| Long Term Equity Investment |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
63.38
-20.17%
|
79.40
-17.72%
|
96.49
-7.79%
|
104.64
|
| Current Liabilities |
|
32.44
-16.61%
|
38.90
+13.74%
|
34.20
+62.96%
|
20.99
|
| Payables And Accrued Expenses |
|
0.30
-80.05%
|
1.49
-53.31%
|
3.20
+111.92%
|
1.51
|
| Payables |
|
0.30
-80.05%
|
1.49
-53.31%
|
3.20
+111.92%
|
1.51
|
| Accounts Payable |
|
0.30
+1762.50%
|
0.02
-98.96%
|
1.54
+293.11%
|
0.39
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
—
|
| Total Tax Payable |
|
0.00
-100.00%
|
1.48
-10.91%
|
1.66
+48.39%
|
1.12
|
| Current Debt And Capital Lease Obligation |
|
6.42
+4.36%
|
6.15
+280.98%
|
1.61
-58.48%
|
3.89
|
| Current Debt |
|
4.87
+6.33%
|
4.58
|
—
|
2.50
|
| Other Current Borrowings |
|
4.87
+6.33%
|
4.58
|
—
|
2.50
|
| Current Capital Lease Obligation |
|
1.54
-1.40%
|
1.57
-2.91%
|
1.61
+16.37%
|
1.39
|
| Current Deferred Liabilities |
|
17.55
-20.01%
|
21.94
+6.68%
|
20.57
+264.63%
|
5.64
|
| Current Deferred Revenue |
|
17.55
-20.01%
|
21.94
+6.68%
|
20.57
+264.63%
|
5.64
|
| Other Current Liabilities |
|
8.17
-12.27%
|
9.32
+5.63%
|
8.82
-11.36%
|
9.95
|
| Total Non Current Liabilities Net Minority Interest |
|
30.94
-23.59%
|
40.50
-34.99%
|
62.29
-25.54%
|
83.65
|
| Long Term Debt And Capital Lease Obligation |
|
9.55
-13.73%
|
11.07
-38.92%
|
18.12
+0.20%
|
18.08
|
| Long Term Debt |
|
—
|
—
|
4.29
+0.49%
|
4.27
|
| Long Term Capital Lease Obligation |
|
9.55
-13.73%
|
11.07
-19.97%
|
13.83
+0.11%
|
13.81
|
| Non Current Deferred Liabilities |
|
21.39
-27.30%
|
29.43
-33.37%
|
44.17
-32.63%
|
65.57
|
| Non Current Deferred Revenue |
|
21.39
-27.30%
|
29.43
-33.37%
|
44.17
-32.63%
|
65.57
|
| Stockholders Equity |
|
49.37
-44.25%
|
88.56
+113.96%
|
41.39
-38.28%
|
67.06
|
| Common Stock Equity |
|
49.37
-44.25%
|
88.56
+113.96%
|
41.39
-38.28%
|
67.06
|
| Capital Stock |
|
4.31
+0.00%
|
4.31
+27.83%
|
3.37
+0.00%
|
3.37
|
| Common Stock |
|
4.31
+0.00%
|
4.31
+27.83%
|
3.37
+0.00%
|
3.37
|
| Share Issued |
|
107.71
+0.00%
|
107.71
+27.85%
|
84.25
+0.00%
|
84.25
|
| Ordinary Shares Number |
|
105.36
+0.14%
|
105.21
+29.33%
|
81.35
+0.67%
|
80.82
|
| Treasury Shares Number |
|
2.35
-5.95%
|
2.50
-13.66%
|
2.89
-15.63%
|
3.43
|
| Additional Paid In Capital |
|
483.88
+0.01%
|
483.81
+17.18%
|
412.89
+0.09%
|
412.54
|
| Retained Earnings |
|
-467.51
-9.45%
|
-427.16
-6.56%
|
-400.85
-5.73%
|
-379.11
|
| Gains Losses Not Affecting Retained Earnings |
|
28.69
+3.96%
|
27.60
+6.24%
|
25.98
-14.17%
|
30.26
|
| Minority Interest |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.38
|
| Total Equity Gross Minority Interest |
|
49.37
-44.25%
|
88.56
+113.96%
|
41.39
-37.93%
|
66.68
|
| Total Capitalization |
|
49.37
-44.25%
|
88.56
+93.86%
|
45.68
-35.96%
|
71.34
|
| Working Capital |
|
67.69
-41.11%
|
114.94
+32.45%
|
86.78
-34.98%
|
133.47
|
| Invested Capital |
|
54.25
-41.76%
|
93.14
+103.89%
|
45.68
-38.13%
|
73.84
|
| Total Debt |
|
15.96
-7.27%
|
17.22
-12.76%
|
19.73
-10.18%
|
21.97
|
| Capital Lease Obligations |
|
11.09
-12.21%
|
12.63
-18.18%
|
15.44
+1.59%
|
15.20
|
| Net Tangible Assets |
|
49.37
-44.25%
|
88.56
+113.96%
|
41.39
-38.28%
|
67.06
|
| Tangible Book Value |
|
49.37
-44.25%
|
88.56
+113.96%
|
41.39
-38.28%
|
67.06
|
| Investmentin Financial Assets |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.62
|
| Investmentsin Associatesat Cost |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-52.79
-45.06%
|
-36.39
-268.89%
|
21.55
+131.45%
|
-68.51
|
| Cash Flow From Continuing Operating Activities |
|
-52.79
-45.06%
|
-36.39
-268.89%
|
21.55
+131.45%
|
-68.51
|
| Net Income From Continuing Operations |
|
-42.18
-51.94%
|
-27.76
-0.10%
|
-27.73
+56.80%
|
-64.20
|
| Depreciation Amortization Depletion |
|
2.70
-2.10%
|
2.76
+9.87%
|
2.51
-0.32%
|
2.52
|
| Depreciation |
|
2.70
-2.10%
|
2.76
+9.87%
|
2.51
-0.32%
|
2.52
|
| Depreciation And Amortization |
|
2.70
-2.10%
|
2.76
+9.87%
|
2.51
-0.32%
|
2.52
|
| Other Non Cash Items |
|
-1.49
+47.03%
|
-2.81
+53.31%
|
-6.01
-463.48%
|
1.65
|
| Stock Based Compensation |
|
4.01
+57.78%
|
2.54
-18.09%
|
3.11
+8.26%
|
2.87
|
| Deferred Tax |
|
0.02
+109.64%
|
-0.20
-152.56%
|
-0.08
-181.25%
|
0.10
|
| Deferred Income Tax |
|
0.02
+109.64%
|
-0.20
-152.56%
|
-0.08
-181.25%
|
0.10
|
| Operating Gains Losses |
|
-0.23
+31.88%
|
-0.34
+68.17%
|
-1.08
+59.93%
|
-2.71
|
| Gain Loss On Investment Securities |
|
-0.23
+31.88%
|
-0.34
+63.80%
|
-0.95
+64.87%
|
-2.71
|
| Change In Working Capital |
|
-17.42
-31.31%
|
-13.26
-127.09%
|
48.96
+1080.89%
|
-4.99
|
| Change In Other Working Capital |
|
-17.42
-31.31%
|
-13.26
-127.09%
|
48.96
+1080.89%
|
-4.99
|
| Investing Cash Flow |
|
-1.02
+74.96%
|
-4.07
-195.21%
|
4.28
+709.40%
|
-0.70
|
| Cash Flow From Continuing Investing Activities |
|
-1.02
+74.96%
|
-4.07
-195.21%
|
4.28
+709.40%
|
-0.70
|
| Net PPE Purchase And Sale |
|
-1.02
+28.07%
|
-1.42
-8.16%
|
-1.31
-86.75%
|
-0.70
|
| Purchase Of PPE |
|
-1.02
+28.07%
|
-1.42
-3.43%
|
-1.37
-93.64%
|
-0.71
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.06
+900.00%
|
0.01
|
| Capital Expenditure |
|
-1.02
+28.07%
|
-1.42
-3.43%
|
-1.37
-93.64%
|
-0.71
|
| Net Investment Purchase And Sale |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-17.00
|
0.00
|
0.00
|
| Sale Of Investment |
|
0.00
-100.00%
|
17.00
|
0.00
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.00
|
0.00
+100.00%
|
-0.13
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
7.94
|
0.00
|
| Net Other Investing Changes |
|
—
|
-2.65
-12.93%
|
-2.35
|
—
|
| Financing Cash Flow |
|
-1.84
-102.61%
|
70.28
+3189.05%
|
-2.27
+92.64%
|
-30.89
|
| Cash Flow From Continuing Financing Activities |
|
-1.84
-102.61%
|
70.28
+3189.05%
|
-2.27
+92.64%
|
-30.89
|
| Net Issuance Payments Of Debt |
|
-1.91
-20.42%
|
-1.58
+39.83%
|
-2.63
+94.16%
|
-45.05
|
| Issuance Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-1.91
-20.42%
|
-1.58
+39.83%
|
-2.63
+94.16%
|
-45.05
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-1.91
-20.42%
|
-1.58
+39.83%
|
-2.63
+94.16%
|
-45.05
|
| Net Long Term Debt Issuance |
|
-1.91
-20.42%
|
-1.58
+39.83%
|
-2.63
+94.16%
|
-45.05
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
71.64
|
0.00
-100.00%
|
14.12
|
| Proceeds From Stock Option Exercised |
|
0.07
-69.06%
|
0.22
-37.01%
|
0.35
+941.18%
|
0.03
|
| Changes In Cash |
|
-55.65
-286.67%
|
29.81
+26.58%
|
23.55
+123.53%
|
-100.10
|
| Effect Of Exchange Rate Changes |
|
-1.35
-300.30%
|
0.67
+12.35%
|
0.60
-91.85%
|
7.35
|
| Beginning Cash Position |
|
149.41
+25.63%
|
118.92
+25.48%
|
94.78
-49.46%
|
187.52
|
| End Cash Position |
|
92.41
-38.15%
|
149.41
+25.63%
|
118.92
+25.48%
|
94.78
|
| Free Cash Flow |
|
-53.81
-42.32%
|
-37.81
-287.40%
|
20.18
+129.15%
|
-69.22
|
| Common Stock Issuance |
|
0.00
-100.00%
|
71.64
|
0.00
-100.00%
|
14.12
|
| Earnings Losses From Equity Investments |
|
—
|
0.00
|
0.00
-100.00%
|
0.01
|
| Interest Paid CFO |
|
-0.52
+32.73%
|
-0.77
+2.41%
|
-0.79
+79.00%
|
-3.76
|
| Interest Received CFO |
|
2.33
-28.24%
|
3.25
+25.38%
|
2.59
+2346.23%
|
0.11
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
71.64
|
0.00
-100.00%
|
14.12
|
| Sale Of Intangibles |
|
0.00
|
0.00
-100.00%
|
7.94
|
0.00
|
| Taxes Refund Paid |
|
-0.02
-109.64%
|
0.20
+152.56%
|
0.08
+181.25%
|
-0.10
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|